Navigation Links
Ironwood Announces Linaclotide European Licensing Agreement with Almirall
Date:5/4/2009

r.

About Linaclotide

Linaclotide is a first-in-class compound in Phase 3 clinical development for the treatment of IBS-C and chronic constipation (CC). Linaclotide demonstrated proof of concept in a comprehensive Phase 2b program, comprised of two clinical studies in over 700 patients with either IBS-C or CC. In patients with IBS-C, linaclotide significantly reduced abdominal pain and bloating and improved bowel function throughout the 12-week treatment period. In patients with CC, linaclotide reduced constipation throughout the 4-week treatment period. In both studies the most common adverse event was diarrhea. Linaclotide is a once daily, orally delivered peptide that acts locally in the gut with no detectable systemic exposure at therapeutic doses. Linaclotide is an agonist of guanylate cyclase type-C, a receptor found on the lining of the intestine. Issued composition of matter patents for linaclotide in the United States and Europe provide protection beyond 2024. In September 2007, Ironwood and Forest Laboratories, Inc. entered into a 50/50 collaboration to co-develop and co-promote linaclotide in United States.

About Irritable Bowel Syndrome with Constipation (IBS-C)

IBS-C is a chronic functional gastrointestinal disorder characterized by abdominal pain and discomfort associated with altered bowel habits. There are currently few available therapies to treat this disorder. In the five major European markets alone, an estimated nine million patients suffer from IBS-C. Patients suffering from IBS-C can be affected physically, psychologically, socially, and economically.

About Almirall

Almirall is an international pharmaceutical company based on innovation and committed to health. Headquartered in Barcelona, Spain, Almirall researches, develops, manufactures, and commercializes its own R&D and licensed drugs with the aim of improving people's health and wellbeing
'/>"/>

SOURCE Ironwood Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
2. Ironwood and Forest to Present Positive Data From Linaclotide Phase 2b IBS-C Study at ACG Annual Scientific Conference
3. Ironwood Raises $50 Million to Advance Linaclotide Through Phase 3
4. Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain
5. Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... Aug. 1, 2014 Dyadic International, Inc. ("Dyadic") ... proprietary technologies are used to develop, manufacture and sell ... biopharmaceutical and industrial enzyme industries, announced today that it ... ended June 30, 2014 after market close on Thursday, ... that day at 5:00 p.m. Eastern Time to discuss ...
(Date:7/31/2014)... 1, 2014 Cipla ... heute bekannt, vor kurzem für OneDose ReadyfusOR™ ... nach chirurgischen Eingriffen eine kommerzielle Zusammenarbeit begonnen ... Union und weiterer europäischer Länder abdeckt. Cipla ... Ropivacain gefüllte OneDose ReadyfusOR später in diesem ...
(Date:7/31/2014)... STAAR Surgical Company (NASDAQ: STAA ) a ... delivery systems for the eye today reported revenue for ... million, a 10% increase over $18.2 million reported for ... basis, revenues grew 11% during the second quarter of ... effect of foreign currency exchange reduced sales by $0.1 ...
Breaking Medicine Technology:Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 2Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 3Cipla und BioQuiddity geben EU-Geschäftspartnerschaft für OneDose-ReadyfusOR zur Schmerzbehandlung nach chirurgischen Eingriffen bekannt 2Cipla und BioQuiddity geben EU-Geschäftspartnerschaft für OneDose-ReadyfusOR zur Schmerzbehandlung nach chirurgischen Eingriffen bekannt 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25STAAR Surgical Reports 10% Second Quarter Revenue Growth 26STAAR Surgical Reports 10% Second Quarter Revenue Growth 27STAAR Surgical Reports 10% Second Quarter Revenue Growth 28STAAR Surgical Reports 10% Second Quarter Revenue Growth 29STAAR Surgical Reports 10% Second Quarter Revenue Growth 30STAAR Surgical Reports 10% Second Quarter Revenue Growth 31
... FARMINGDALE, N.Y., Nov. 2, 2011 Misonix, Inc. ... company that designs, manufactures, and markets innovative therapeutic ... cosmetic surgery, neurosurgery, laparoscopic surgery and other surgical ... Ultrasonic Bone Cutting System and the SonaStar® Ultrasonic ...
... 2011 Perrigo Company (Nasdaq: PRGO ; TASE) ... Drug Administration (FDA) a New Drug Application (NDA) for testosterone ... the owner of the Reference Listed Drug of its filing. ... the United States District Court for the District of New ...
Cached Medicine Technology:Misonix Announces its Exhibition at the European Association of Neurosurgical Societies 2Misonix Announces its Exhibition at the European Association of Neurosurgical Societies 3Perrigo Confirms Filing for Testosterone Gel 1.0% and Announcement of Patent Infringement Lawsuit by Abbott 2
(Date:8/2/2014)... Seattle, Wa (PRWEB) August 02, 2014 According ... Vkool.com, this is a comprehensive dating guide for women. The ... attract the man they want easily. The book also teaches ... commitment issues. , Vkool reveals in its review that ...     Chapter 1 – What’s Your Relationship Story? , ...
(Date:8/2/2014)... Lakewood Park Apartment Homes , located ... side, has undertaken a project that promises to help ... sense, while improving the “green” appearance of its already ... announced that Lakewood Park is currently preparing garden plots ... about being able to offer this opportunity to our ...
(Date:8/2/2014)... 02, 2014 When the Black Hat conventioneers ... this year, one thing can be always counted on, plenty ... as fear, uncertainty and doubt. The run-up has already ... article published by Reuters on July 31st about how ... or keyboard to successfully infect a system with malware, completely ...
(Date:8/1/2014)... 2014 Cannabis use among young people has ... to 17 having used marijuana at least once and 17 ... “Say ‘No’ to Drugs, Say ‘Yes to Life,’ volunteers from ... youth this summer with factual information about drugs, to help ... Hamburg “Say ‘No’ to Drugs, Say ‘Yes’ to Life,” volunteers ...
(Date:8/1/2014)... brain plays a central role in regulating appetite and ... in the brain,s control of food intake and body ... process has been unclear. A new study ... that PPARγ activity in a type of neuron known ... response to high-fat diet. Sabrina Diano and colleagues ...
Breaking Medicine News(10 mins):Health News:Girl Gets Ring System Review Exposes Jonathan Green's Dating Guide For Women – Vkool.com 2Health News:Girl Gets Ring System Review Exposes Jonathan Green's Dating Guide For Women – Vkool.com 3Health News:Lexington’s Lakewood Park Apartments Getting Into Gardening 2Health News:Black Hat USA 2014 Will Again Stress Need for Security Basics with Glimpse of What May Lie Ahead 2Health News:Black Hat USA 2014 Will Again Stress Need for Security Basics with Glimpse of What May Lie Ahead 3Health News:Black Hat USA 2014 Will Again Stress Need for Security Basics with Glimpse of What May Lie Ahead 4Health News:Black Hat USA 2014 Will Again Stress Need for Security Basics with Glimpse of What May Lie Ahead 5Health News:Addressing a Serious Issue Affecting German Teens 2
... committee Sunday said medicines sold in shops would indicate ... 2. ,The decision was taken in a meeting ... of chemicals, fertilizers and steel. The members were discussing ... members decided that the 354 drugs in the national ...
... is where the Codex Alimentarius Commission’s role is crucial. If ... uphill task to maintain standards in taste and safety. ... to the European community. This is indeed a combined worthy ... Agriculture Organization of the United Nations. ,They are ...
... The government has planned to alter citeria for jobless benefit ... illness under //reforms being unveiled this week. ,Work and ... off benefit and into work following the publishing of his ... the personal capability assessment which is used to decide whether ...
... Recently an UCLA study by a team of researchers ... carotid atheromas formation in patients //at a higher risk ... link may be due to blockages containing calcium in ... carotid artery. ,These blockages, or atheromas, contain ...
... the disease strides ahead with greater determination from obscurity to ... why is the pandemic// outpacing us, or are countries acting ... million people and affected another 40 million worldwide? ... York for the review meeting to the United Nations General ...
... consider Medical Council of India seniority on appointment in ... ,Talking to reporters here Association General Secretary, ... about 34,000 doctors are unemployed in India in which ... is recruiting doctors for government health services, the government ...
Cached Medicine News:Health News:AIDS: Why the pandemic outpaces us 2Health News:AIDS: Why the pandemic outpaces us 3
... has been designed for use with Bioneer's ... can handle 96 samples (Plasmid DNA, Genomic ... and purification. While conventional kits use centrifugal ... BioVac 96 Vacuum Manifold uses vacuum pressure ...
Plastic Tray Type Vacuum Manifold...
... manifold is designed to efficiently process ... holds one deep well plate and ... are drawn through the wells ... microplates. The base holds and ...
QIAvac 96 is designed for efficient processing of QIAGEN 96-well plates....
Medicine Products: